CSIMarket
 
Verona Pharma Plc  (VRNA)
Other Ticker:  
 
 
Price: $18.1900 $0.97 5.633%
Day's High: $18.49 Week Perf: 3.18 %
Day's Low: $ 17.24 30 Day Perf: -0.87 %
Volume (M): 479 52 Wk High: $ 23.81
Volume (M$): $ 8,709 52 Wk Avg: $18.46
Open: $17.50 52 Wk Low: $11.83



 Market Capitalization (Millions $) 10,989
 Shares Outstanding (Millions) 604
 Employees 64
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -54
 Cash Flow (TTM) (Millions $) 44
 Capital Exp. (TTM) (Millions $) 0

Verona Pharma Plc
Verona Pharma Plc is a biopharmaceutical company focused on developing innovative medicines for the treatment of respiratory diseases. The company's lead product candidate, ensifentrine, is a first-in-class bronchodilator and anti-inflammatory agent that has the potential to be used in multiple respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.

The company was founded in 2005 and is headquartered in London, UK. It has a research and development center in Cardiff, UK, and a clinical development team in the US. Verona Pharma has a global presence and operates in several countries, including the UK, US, Canada, and Australia.

Verona Pharma has a deep and experienced management team, led by CEO Dr. David Zaccardelli, who has extensive experience in drug development and commercialization. The company has a strong scientific team that has published numerous peer-reviewed articles in leading scientific journals.

Verona Pharma has a robust pipeline of product candidates, including nebulized ensifentrine for the treatment of COPD, dry powder ensifentrine for the treatment of asthma, and nebulized ensifentrine for the treatment of cystic fibrosis. The company is also developing a second-generation bronchodilator, RPL554, for the treatment of chronic obstructive pulmonary disease (COPD).

Verona Pharma is focused on bringing its innovative therapies to patients as quickly as possible. The company has a fast-paced, entrepreneurial culture and is committed to attracting and retaining top talent to drive its growth and success. Verona Pharma has a strong commitment to patient-centricity, focusing on delivering meaningful benefits to patients and their families in respiratory disease treatment.


   Company Address: 3 More London Riverside London 0
   Company Phone Number: 283 4200   Stock Exchange / Ticker: NASDAQ VRNA
   VRNA is expected to report next financial results on March 06, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Verona Pharma Plc

Verona Pharma Plc's Financial Successes Propel Growth Amid Lackluster Revenue in Q4 2023

Verona Pharma Plc, a prominent player in the pharmaceutical industry, has recently made strategic moves to strengthen its financial position, enabling continued growth. Despite a minor increase in borrowings, the company has successfully enhanced its Leverage Ratio, surpassing its own average and outperforming 16 competitors within the industry. These developments have significant implications for the company's overall trajectory.
Verona Pharma Plc has managed to boost its Leverage Ratio to 0.11 in the third quarter of 2023. This ratio exceeds the company's typical average and ranks higher than its Leverage Ratio in the previous quarter. What makes this achievement even more noteworthy is that 16 other companies in the industry reported lower Leverage Ratios during the same period, highlighting Verona Pharma's superior financial standing.

Financing Agreement

Verona Pharma Strengthens Financial Foundation and Secures $400 Million Debt Facility for Future Growth

Published Tue, Jan 2 2024 7:00 AM UTC



Verona Pharma Plc, a prominent player in the pharmaceutical industry, has recently announced strategic moves to strengthen its financial position, enabling continued growth. Despite a minor increase in borrowings, Verona Pharma Plc has successfully enhanced its Leverage Ratio, surpassing its own average and outperforming 16 competitors within the industry. This art...

Verona Pharma Plc

Verona Pharma Plc's Third Quarter Results Reveal Surprising $-16.311 Million Operating Loss

Verona Pharma Plc, an emerging growth entity in the pharmaceutical industry, has recently released its financial results for the period of July to September 30, 2023. Surprisingly, investors did not anticipate any significant changes in the company's top-line during this reporting season. However, they have noticed a noteworthy operating loss of $-16.311 million during the same period.
To put these results into context, it is important to compare them with the company's previous performances. Looking back at the third quarter of 2022, Verona Pharma Plc announced an operating loss of $-15.128 million. Therefore, despite the company not reporting its revenue for the third quarter of 2023, it can be inferred that there has been an improvement in its financials.

Verona Pharma Plc

Verona Pharma Reports Noteworthy Improvement in Q2 2023 Operating Shortfall, Surprises Investors

Financial news report:
Verona Pharma Plc, a pharmaceutical company, is set to report its financial results for the period of April to June 30, 2023 on August 08, 2023. Investors had not anticipated any significant changes in revenue during this reporting season. However, they have been closely monitoring the company's operating shortfall, which stood at $-9.965 million during the same period. This improvement in the operating shortfall compared to the corresponding period last year, which was -$20.508 million, has led to increased investor optimism.
The decrease in the operating shortfall can be considered good news, especially in the absence of more significant benchmarks for comparison. Verona Pharma appears to be making efforts to diversify its revenue streams, which could help mitigate the diminishing returns. In the second quarter of 2022, the operating shortfall stood at $-17.766 million, but it is expected to decrease to $-8.807 million in the April to June 30, 2023 time-frame.

Verona Pharma Plc

Verona Pharma Plc Surpasses Expectations with Strong Q1 Performance, Despite Operating Deficit

In the Major Pharmaceutical Preparations sector, there are a few lesser-known businesses making their way to the forefront. Among these is Verona Pharma Plc, which has announced a $-22.199 million operating deficit for the first quarter of 2023. While this may seem like negative news, it is worth noting that the company has actually surpassed its performance in the same quarter of the previous year.
As a company that primarily operates in the development cycle, Verona Pharma's Q1 2023 result is a significant conclusion. However, it's not all bad news for the company. The good news is that the diminishing returns have decreased to $-16.743 million from the $-24.837 million recorded in the first quarter of 2022. This is a positive sign and may help Verona Pharma become a standout leader in the industry.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com